Most cited papers from Deltagen (United States)

Deltagen (United States)

What are the most cited papers from Deltagen (United States)?

The most cited paper from Deltagen (United States) is "An integrative genomics approach to infer causal associations between gene expression and disease" (Eric E. Schadt et al., 2005), with 1,091 citations. Next come "GFRα1 Is an Essential Receptor Component for GDNF in the Developing Nervous System and Kidney" (566) and "Loss of Nuclear Receptor SHP Impairs but Does Not Eliminate Negative Feedback Regulation of Bile Acid Synthesis" (353).

Published TypeFieldAccessCitations

Showing 50 of 72 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	An integrative genomics approach to infer causal associations between gene expression and disease Eric E. Schadt et al. · Nature Genetics Open access	19 Jun 2005	1,091
2	GFRα1 Is an Essential Receptor Component for GDNF in the Developing Nervous System and Kidney Grace Cacalano, Isabel Fariñas, Li-Chong Wang et al. · Neuron Open access	Jul 1998	566
3	Loss of Nuclear Receptor SHP Impairs but Does Not Eliminate Negative Feedback Regulation of Bile Acid Synthesis Thomas A. Kerr, Shigeru Saeki, Manfred P Schneider et al. · Developmental Cell Open access	Jun 2002	353
4	The G s -Linked Receptor GPR3 Maintains Meiotic Arrest in Mammalian Oocytes Lisa M. Mehlmann, Yoshinaga Saeki, Shigeru Tanaka et al. · Science	10 Dec 2004	336
5	A Genome-wide Drosophila Screen for Heat Nociception Identifies α2δ3 as an Evolutionarily Conserved Pain Gene G. Gregory Neely et al. · Cell Open access	Nov 2010	327
6	Role of GPR81 in lactate-mediated reduction of adipose lipolysis Tian‐Quan Cai, Ning Ren, Lan Jin et al. · Biochemical and Biophysical Research Communications	25 Oct 2008	308
7	Synergy between LRH-1 and β-Catenin Induces G1 Cyclin-Mediated Cell Proliferation Oronza Antonietta Botrugno, Elisabeth Fayard, Jean‐Sébastien Annicotte et al. · Molecular Cell Open access	Aug 2004	277
8	The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration and Activation Yaël Mamane, Chi Chung Chan, Geneviève Lavallée et al. · Diabetes Open access	6 Jul 2009	189
9	Kv2.1 Ablation Alters Glucose-Induced Islet Electrical Activity, Enhancing Insulin Secretion David Aaron Jacobson, Andrey V. Kuznetsov, James P. Lopez et al. · Cell Metabolism Open access	Sep 2007	185
10	A Computational Ensemble Pharmacophore Model for Identifying Substrates of P-Glycoprotein Julie E. Penzotti, Michelle L. Lamb, Erik Evensen et al. · Journal of Medicinal Chemistry	26 Mar 2002	179
11	Therapeutic opportunities from muscarinic receptor research Richard M. Eglen, Agnès Choppin, NIKKI A. WATSON · Trends in Pharmacological Sciences Review	Aug 2001	170
12	Sulfation of L-Selectin Ligands by an HEV-Restricted Sulfotransferase Regulates Lymphocyte Homing to Lymph Nodes Stefan Hemmerich, Annette Bistrup, Mark S. Singer et al. · Immunity Open access	Aug 2001	163
13	RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Shukui Qin, Richard S. Finn, Masatoshi Kudo et al. · Future Oncology Open access	10 Apr 2019	153
14	Phosphorylation by Sky1p promotes Npl3p shuttling and mRNA dissociation Wendy V. Gilbert, Christian W. Siebel, Christine Guthrie · RNA Open access	Feb 2001	143
15	Targeted Disruption of Peptide TransporterPept1Gene in Mice Significantly Reduces Dipeptide Absorption in Intestine Yongun Hu, David Eugene Smith, Ke Ma et al. · Molecular Pharmaceutics Open access	6 Nov 2008	123
16	Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 Diabetes Yanfang Liu, M. D. Michael, Shera F. Kash et al. · Endocrinology	27 Oct 2006	114
17	Performance of 3D-Database Molecular Docking Studies into Homology Models Connie M. Oshiro, Erin K. Bradley, John E. Eksterowicz et al. · Journal of Medicinal Chemistry	2004	101
18	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Peter Hillmen, Jennifer R. Brown, Barbara F. Eichhorst et al. · Future Oncology Open access	24 Mar 2020	83
19	An extensible and systematic force field, ESFF, for molecular modeling of organic, inorganic, and organometallic systems Shenghua Shi, Lisa Yan, Yang Yang et al. · Journal of Computational Chemistry	14 May 2003	78
20	Disturbances in hepatic cell-cycle regulation in mice with assembly-deficient keratins 8/18 Diana M. Toivola, Mikko Nieminen, Michael Hesse et al. · Hepatology Open access	Dec 2001	71
21	Lack of the alanine–serine–cysteine transporter 1 causes tremors, seizures, and early postnatal death in mice Xinmin Xie, Theodore Constantine Dumas, Lamont S. Tang et al. · Brain Research	19 Jul 2005	67
22	Susceptibility to Pneumocystis carinii in Mice Is Dependent on Simultaneous Deletion of IFN-γ and Type 1 and 2 TNF Receptor Genes Daniel G. Rudmann, Angela M. Preston, Mark W. Moore et al. · The Journal of Immunology Open access	Jul 1998	66
23	Modulation of allergic inflammation in mice deficient in TNF receptors Daniel G. Rudmann, Mark W. Moore, Jeffery S. Tepper et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology	Dec 2000	61
24	Ketene Dithioacetals in the Aza-Diels−Alder Reaction with N-Arylimines: A Versatile Approach to Tetrahydroquinolines, 2,3-Dihydro-4-quinolones, and 4-Quinolones Dai Cheng, Jinglan Zhou, Eddine Saiah et al. · Organic Letters	20 Nov 2002	59
25	Cellular Recognition of Trimyristoylated Peptide or Enterobacterial Lipopolysaccharide via Both TLR2 and TLR4 Stephan Spiller, Stefan Dreher, Guangxun Meng et al. · Journal of Biological Chemistry Open access	13 Mar 2007	47
26	Simple epithelial keratins are dispensable for cytoprotection in two pancreatitis models Diana M. Toivola, Hélène Baribault, Thomas Michael Magin et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology	Dec 2000	46
27	Realities of High-Throughput Liquid Chromatography/Mass Spectrometry Purification of Large Combinatorial Libraries: A Report on Overall Sample Throughput Using Parallel Purification John J. Isbell, Rongda Xu, Zekun Cai et al. · Journal of Combinatorial Chemistry	29 Aug 2002	44
28	Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study Gavin Cull, Jan A. Burger, Stephen Opat et al. · British Journal of Haematology Open access	16 Dec 2021	40
29	Pamiparib Monotherapy for Patients with Germline BRCA1/2 -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study Xiaohua Wu et al. · Clinical Cancer Research Open access	29 Nov 2021	39
30	Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure–activity relationships of diamine derivatives Wilna J. Moree, Ken-ichiro Kataoka, Michele M. Ramirez‐Weinhouse et al. · Bioorganic & Medicinal Chemistry Letters Open access	18 Sep 2004	39
31	A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma Martin H. Dreyling, Constantine Si Lun Tam, Michael Wang et al. · Future Oncology Open access	28 Sep 2020	36
32	A radiation hybrid transcript map of the mouse genome Philip Avner et al. · Nature Genetics	Oct 2001	36
33	Muscarinic receptors in isolated urinary bladder smooth muscle from different mouse strains Agnès Choppin · British Journal of Pharmacology Open access	Oct 2002	35
34	Evaluation of a Novel Shape-Based Computational Filter for Lead Evolution: Application to Thrombin Inhibitors Jayashree Srinivasan, Angelo J. Castellino, Erin K. Bradley et al. · Journal of Medicinal Chemistry	7 May 2002	33
35	The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards Gaohong Dong, Bo Huang, Yu-Wei Wayne Chang et al. · Pharmaceutical Statistics	31 Oct 2019	32
36	A Screen for Modifiers ofdecapentaplegicMutant Phenotypes Identifieslilliputian, the Only Member of the Fragile-X/Burkitt's Lymphoma Family of Transcription Factors inDrosophila melanogaster Maureen A. Su, Robert G. Wisotzkey, Stuart J. Newfeld · Genetics	Feb 2001	32
37	Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator Kun Wang, Xueting Yao, Miao Zhang et al. · CPT Pharmacometrics & Systems Pharmacology Open access	9 Mar 2021	31
38	Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper Divya Samineni et al. · Clinical Pharmacology & Therapeutics Open access	16 May 2024	30
39	RGS4, a GTPase activator, improves renal function in ischemia–reperfusion injury Andrew M. Siedlecki, Xiaohua Jin, Winston Thomas et al. · Kidney International Open access	16 Mar 2011	28
40	Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series Wilna J. Moree, Ken-ichiro Kataoka, Michele M. Ramirez‐Weinhouse et al. · Bioorganic & Medicinal Chemistry Letters Open access	12 Feb 2008	26
41	Stable expression of Anthozoa fluorescent proteins in mammalian cells Burt T. Richards, Ludmilla Zharkikh, Forrest Hsu et al. · Cytometry Open access	20 May 2002	24
42	Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program Gerald R. Galluppi, Malidi Ahamadi, Souvik Bhattacharya et al. · Clinical Pharmacology & Therapeutics Open access	22 Mar 2024	20
43	Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors Nageshwar R. Budha, Chi‐Yuan Wu, Zhiyu Tang et al. · CPT Pharmacometrics & Systems Pharmacology Open access	4 Nov 2022	19
44	Chapter 9. Anticoagulants: Inhibitors of the factor vila/tissue factor pathway Leslie A. Robinson, Eddine Saiah · Annual reports in medicinal chemistry Book chapter	2002	18
45	LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL Jacob Drobnyk Soumerai et al. · Hematological Oncology Open access	Jun 2023	17
46	Comparing Performance of Computational Tools for Combinatorial Library Design Erik Evensen, John E. Eksterowicz, Robert V. Stanton et al. · Journal of Medicinal Chemistry	18 Oct 2003	15
47	Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors Wilna J. Moree, P.H. Goldman, Anthony J. DeMaggio et al. · Bioorganic & Medicinal Chemistry Letters Open access	28 Jul 2008	14
48	Microsatellite marker panels for use in high-throughput genotyping of mouse crosses Olga A. Iakoubova, Christine Olsson, Katherine M. Dains et al. · Physiological Genomics Open access	8 Sep 2000	13
49	Overexpression of the β‐catenin binding domain of cadherin selectively kills colorectal cancer cells Michael M. Pierce, Chunwei Wang, Mark Stump et al. · International Journal of Cancer Open access	6 Aug 2003	13
50	No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects Song Mu, Börje Darpö, Zhiyu Tang et al. · Clinical and Translational Science Open access	7 Mar 2020	12

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.